$0.74
+0.00 (+0.57%)
Open$0.75
Previous Close$0.73
Day High$0.75
Day Low$0.72
52W High$2.35
52W Low$0.53
Volume—
Avg Volume2.31M
Market Cap155.70M
P/E Ratio—
EPS$-0.47
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+4,791.1% upside
Current
$0.74
$0.74
Target
$36.15
$36.15
$26.32
$36.15 avg
$48.95
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 59.14M | 52.95M | 62.98M |
| Net Income | 4.93M | 4.47M | 5.16M |
| Profit Margin | 8.3% | 8.4% | 8.2% |
| EBITDA | 5.59M | 4.86M | 6.72M |
| Free Cash Flow | 3.58M | 3.18M | 3.67M |
| Rev Growth | +23.4% | +5.7% | +6.5% |
| Debt/Equity | 0.46 | 0.42 | 0.50 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |